PMID- 31172456
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231012
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 10
IP  - 4
DP  - 2019 Aug
TI  - Association of OSAHS Hypoxia Indicators with Early Renal Injury and Serum 
      Fibroblast Growth Factor 21 in Obese Type 2 Diabetic Patients.
PG  - 1357-1368
LID - 10.1007/s13300-019-0639-x [doi]
AB  - OBJECTIVE: This study aimed to explore the association of obstructive sleep 
      apnea-hypopnea syndrome (OSAHS) hypoxia indicators with early renal injury and 
      serum fibroblast growth factor 21 (FGF21) in obese type 2 diabetic patients. 
      METHODS: A total of 109 obese patients with type 2 diabetes mellitus (T2DM) were 
      recruited, including 70 males and 39 females, with an average age of 
      52.77 +/- 13.57 years and average BMI of 29.08 +/- 4.36 kg/m(2). Overnight sleep 
      monitoring was performed with a portable monitor to record respiratory parameters 
      [apnea-hypopnea index (AHI), oxygen desaturation index (ODI), lowest oxygen 
      saturation (LSaO(2)), mean oxygen saturation (MSaO(2)/MPO(2)) and cumulative time 
      of oxygen saturation < 90% (CT < 90%)]. Ultrasonography was done to detect the 
      quantitative liver fat content (LFC). The urine microalbumin and creatinine ratio 
      (ACR) were determined by immunoturbidimetry. FGF21 was measured at baseline by 
      enzyme-linked immunosorbent assay. Patients were divided into the proteinuria 
      group (n = 42) and non-proteinuria group (n = 67). Correlation analysis and 
      multivariate linear regression analysis were used to analyze the related data. In 
      addition, patients were divided into the T2DM without OSAHS group (n = 16) and 
      T2DM with OSAHS group (n = 93) according to the AHI value. The correlation 
      analysis was used to assess the relationship between FGF21 and clinical 
      variables. RESULTS: (1) ACR positively correlated with waist circumference (WC), 
      AHI, ODI, CT < 90% and LFC, but negatively with MSaO(2) and LSaO(2). (2) AHI, 
      ODI, CT < 90% and LFC were independent risk factors for ACR, LSaO(2) and MSaO(2) 
      was a protective factor. (3) Serum FGF21 decreased in the OSAHS group compared 
      with the non-OSAHS group. After adjustment for age, WC and TG, FGF21 correlated 
      negatively with AHI, but positively with MSaO(2). CONCLUSIONS: AHI, ODI, CT < 90% 
      and LFC are independent risk factors for ACR. FGF21 is associated with hypoxia 
      indicators, and improving OSAHS status and reducing liver fat content may be 
      helpful for the prevention and treatment of early diabetic nephropathy (DN). 
      CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-IOR-15006225.
FAU - Yu, Weinan
AU  - Yu W
AD  - Department of Endocrinology, Huai'an Hospital Affiliated to Xuzhou Medical 
      University and Huai'an Second People's Hospital, Huai'an, 223002, Jiangsu, China.
FAU - Wang, Xiaoqing
AU  - Wang X
AD  - Department of Endocrinology, Huai'an Hospital Affiliated to Xuzhou Medical 
      University and Huai'an Second People's Hospital, Huai'an, 223002, Jiangsu, China.
FAU - Ni, Yaojun
AU  - Ni Y
AD  - Department of Cardiothoracic Surgery, Huai'an Hospital Affiliated to Nanjing 
      Medical College and Huai'an First People's Hospital, Huai'an, 223002, Jiangsu, 
      China.
FAU - Huai, De
AU  - Huai D
AD  - Department of Otolaryngology, Huai'an Hospital Affiliated to Xuzhou Medical 
      University and Huai'an Second People's Hospital, Huai'an, 223002, Jiangsu, China.
FAU - Hao, Hairong
AU  - Hao H
AD  - Department of Endocrinology, Huai'an Hospital Affiliated to Xuzhou Medical 
      University and Huai'an Second People's Hospital, Huai'an, 223002, Jiangsu, China.
FAU - Li, Qingjun
AU  - Li Q
AD  - Department of Endocrinology, Jiangning Hospital Affiliated to Nanjing Medical 
      University, Nanjing, 211100, Jiangsu, China.
FAU - Liu, Ziyu
AU  - Liu Z
AD  - Department of Endocrinology, Huai'an Hospital Affiliated to Xuzhou Medical 
      University and Huai'an Second People's Hospital, Huai'an, 223002, Jiangsu, China.
FAU - Wen, Surong
AU  - Wen S
AD  - Department of Endocrinology, Huai'an Hospital Affiliated to Xuzhou Medical 
      University and Huai'an Second People's Hospital, Huai'an, 223002, Jiangsu, China.
FAU - Cheng, Liang
AU  - Cheng L
AD  - Department of Endocrinology, Huai'an Hospital Affiliated to Xuzhou Medical 
      University and Huai'an Second People's Hospital, Huai'an, 223002, Jiangsu, China.
FAU - Hu, Wen
AU  - Hu W
AD  - Department of Endocrinology, Huai'an Hospital Affiliated to Xuzhou Medical 
      University and Huai'an Second People's Hospital, Huai'an, 223002, Jiangsu, China. 
      huwen787878@163.com.
LA  - eng
GR  - 81700776/Young Scientists Fund (CN)/
GR  - HAS201611-04/Key R&D Program of Huaian City, Jiangsu Province/
PT  - Journal Article
DEP - 20190606
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC6612341
OTO - NOTNLM
OT  - Fibroblast growth factor 21
OT  - Obesity
OT  - Obstructive sleep apnea-hypopnea syndrome
OT  - Type 2 diabetes mellitus
OT  - Urine microalbumin and creatinine ratio
EDAT- 2019/06/07 06:00
MHDA- 2019/06/07 06:01
PMCR- 2019/06/06
CRDT- 2019/06/08 06:00
PHST- 2019/04/11 00:00 [received]
PHST- 2019/06/07 06:00 [pubmed]
PHST- 2019/06/07 06:01 [medline]
PHST- 2019/06/08 06:00 [entrez]
PHST- 2019/06/06 00:00 [pmc-release]
AID - 10.1007/s13300-019-0639-x [pii]
AID - 639 [pii]
AID - 10.1007/s13300-019-0639-x [doi]
PST - ppublish
SO  - Diabetes Ther. 2019 Aug;10(4):1357-1368. doi: 10.1007/s13300-019-0639-x. Epub 
      2019 Jun 6.